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1. Introduction
Despite the significant success 
in treatment of patients with myo-
cardial infarction (MI) achieved 
during last decades, it remains one 
of the most significant causes of 
death worldwide. Course of the 
acute phase and long-time prog-
nosis of MI patients depend on 
the grade of coronary artery (CA) 
atherothrombotic injury, time to 
reperfusion and utilized method 
[1], and also on comorbidities such 
as diabetes mellitus (DM), chron-
ic renal disease, atrial fibrillation 
(AF) [2]. AF is the most common 
arrhythmia worldwide. It burdens 
15.5 % of MI cases [3] and is as-
sociated with 40–50 % mortality 
increase [4], rises the risk of com-
plications in an acute period, hos-
pital readmissions, major adverse 
cardiac events (MACEs) [5]. 
The rise of left ventricu-
lar (LV) pressure in response to 
ischemia and necrosis of LV wall 
during MI leads to acute left atri-
um pressure increase, stretching, 
structural and electrical remod-
eling of its wall which predis-
poses to AF. In turn, high heart 
rate during AF and loss of atrial 
contribution to cardiac output 
decreases left ventricular pump 
function and coronary perfusion, 
burdening the course of the MI 
[5]. One of the mechanisms to 
compensate the increase of pres-
sure in cardiac chambers is acti-
vation of natriuretic peptides syn-
thesis. Physiologic roles of these 
molecules are increase of diuresis, 
sodium excretion, vasodilatation. 
Brain natriuretic peptide (BNP) 
or its inactive fragment (NT proB-
NP) are markers of left ventricular 
dysfunction available for use in 
clinical practice [6].
Our aim was to study the 
predictive value of NT proBNP 
regarding the risk of AF and clin-
ical presentation features in acute 
phase of ST-segment elevation 
MI (STEMI).
2. Methods
We examined 56 patients with STEMI and AF who were 
consequentially admitted to the Communal non-profit enter-
prise of the Kharkiv Regional Council “Regional Clinical Hos-
pital” in 2017–2018 and did undergo the primary percutaneous 
coronary intervention (PCI). STEMI was diagnosed according 
to the ECS Guidelines (2017) [7]. Presence of AF was eval-
uated according to ESC/EHRA Guidelines (2016) [8]. Study 
design was approved by Ethics committee of Kharkiv medical 
academy of postgraduate edu-
cation. According to Helsinki 
declaration, all the patients were 
informed regarding aim and 
methods of the current study 
and had provided the written 
informed consent.
35 (62.5 %) patients had the 
new-onset AF (group 1), 21 (37.5 %) 
patients had pre-existind AF 
(group 2). Inclusion criterions 
were age over 18 years, hospital-
ization during the first 12 hours 
of STEMI, pre-existing or new- 
onset AF. Non-inclusion criteria 
were previous MI, severe comor-
bidities, inability to understand 
and/or sign the informed con-
sent. Control group consisted 
of 60 patients with STEMI who 
had no AF (group 3). Age and 
gender of patients in group 3 we- 
re statistically comparable with 
parameters of the entire popu- 
lation. 
Patients were treated accord-
ing to ECS Guidelines (2017) 
[7]. Blood samples were drawn 
immediately before PCI. Cor-
onary angiography and cardi-
ac ultrasound were performed 
according to the routine local 
protocols. 
The primary endpoint was 
combined event (major adverse 
cardiac events – MACEs) that 
occurred during index STEMI 
hospitalization. MACEs were de-
fined as the composite of CV 
death, acute LV heart failure, re-
infarction, stroke/TIA, ventricu-
lar fibrillation.
As for statistical data anal-
ysis, continuous variables were 
presented as mean ± standard 
deviation when they were nor-
mally distributed, or median and 
interquartile range if otherwise. 
Categorical variables were pre-
sented as frequencies and percent-
ages. Mann-Whitney and Wald- 
Wolfowitz criteria were used for 
intergroup differences and quan-
titative values. The qualitative va- 
riables were expressed as percentages, and were analyzed by the χ2 
test and exact Fisher test. Receiver operating characteristic (ROC) 
curve analysis was performed for detection of well-balanced cut-
off points. All differences were considered statistically significant 
with p<0.05. 
3. Results
Patients with AF had the following characteristics. There 
were 53.6 % of males and 46.4 % of females, mean age was 
68.26±12.39 years. 92.9 % of patients had a history of hyperten-
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sion, 39.3 % had DM, 32.1 % had obesity, 21.4 % were smokers, 
12.3 % had angina before index STEMI. 
Group 3 patients were more likely to be smokers than 
patients in group 2 (р2-3=0.037). They had significantly lower 
mean heart rate at admission (р1-3=0.013, р2-3=0.015) and lower 
admission glycaemia (р2-3=0.020), higher admission hemo-
globin (р1-3=0.004). Group 1 patients were more likely to have 
anterior STEMI compared to the group 3 (р1-3=0.035). Patients 
with AF were more likely to have MACEs (р1-3=0.045). Only 
patients in groups 1 and 2 had Killip IV acute heart failure 
(Table 1). Prevalence of DM, arterial hypertension, obesity, 
stable angina before MI, white blood cell count at admission, 
peak troponin I level, glomerular filtration rate (GFR) did not 
differ between groups. Prescription rate of the main drug classes 
recommended for STEMI treatment (angiotensin converting 
enzyme inhibitors/angiotensin receptor blockers, beta-blockers, 
aspirin, clopidogrel/ticagrelor, statins) was similar in all groups. 
Patients in group 3 were less likely to take warfarin (р1-3 =0.0001, 
р2-3 =0.014) or new oral anticoagulants (р1-3=0.0001, р2-3=0.0001) 
because AF is the main indication for those drugs.
As for coronary angiography results, patients with intact CA 
were present only in group 1. Patients in group 2 were signifi-
cantly more likely to have three-vessel injury than groups 1 and 
3 (р1-2=0.019, р2-3=0.001). Patients in group 1 were more likely 
to have left anterior descending artery as an infarction-related 
artery (IRA) than patients in group 3 (р1-3=0.049) while patients 
in group 2 were significantly more likely to have right coronary 
artery as IRA (р1-2=0.042). 
According to the ultrasonic data analysis, left atrium 
end-systolic diameter was significantly higher in group 2 than 
in groups 1 and 3 (р1-2=0.007, р2-3=0.0003). Ejection fraction 
was lower (р1-3=0.0001, р2-3=0.043) and mean pulmonary artery 
pressure was higher in groups 1 and 2 than in group 3 (р1-3= 
=0.007, р2-3=0.0002). 
NT proBNP level in entire population was 1788.00 (610.90; 
3070.0) pg/ml: 2149.00 (439.20; 3429.00) in group 1; 1305.00 
(610.90–2183.00) pg/ml in group 2. In group 3 it was signifi-
cantly lower: 212.80 (26.70–802.60); р1-3=0.001 р2-3=0.005. We 
revealed correlation between NT proBNP and age of patients 
(r=0.433; р=0.012), stable angina before STEMI (r=0.42137; 
р=0.015), admission glycaemia (r=0.359; р=0.019), mean pul-
monary artery pressure (r=0.520; р=0.047), body mass in-
dex (r=–0.457; р=0.022), plasma potassium level (r=–0.3517; 
р=0.048), GFR (r=–0.520; р=0.04).
We performed ROC analysis in order to study the predic-
tive value of NT proBNP regarding the risk of new-onset AF. 
Group 2 patients were excluded from this analysis. Cut-off 
point of NT proBNP level was >1050 pg/ml (sensitivity 63.6 %, 
specificity 92.3 %, area under curve 0.839 (95 % CI 0.676 to 
0.941) – Fig. 1. 
Table 1
Clinical characteristics of examined patients
Parameter Entire population (n=56)
Group 1  
(n=35)
Group 2  
(n=21)
Group 3  
(n=37) p-level
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Fig. 1. ROC-curve for prediction of AF in STEMI patients using 
NT proBNP level
ROC analysis of predictive value of NT proBNP level regard-
ing the risk of MACE in STEMI acute period revealed the cut-off 
point >2189 pg/ml (sensitivity 66.7 %, specificity 83.8 %, area 
under curve 0.839 (95 % CI 0.644 to 0.896) – Fig. 2.
4. Discussion and conclusions
It was shown in our study that NT proBNP is higher in 
STEMI patients who have atrial fibrillation. Increased level of 
NT proBNP is associated with the risk of adverse events in acute 
STEMI phase.
BNP or NT-proBNP is a significant predictor of prognosis in 
patients with MI. Admission plasma BNP and NT-proBNP con-
centrations are associated with all-cause mortality at long-term 
follow-up and with risk of hospitalizations with heart failure 
[9]. Plasma BNP/NT-proBNP concentration increases instantly 
after MI, and the grade of increase is related to the severity of 
ischemia [10]. Patients with smaller infarctions tend to have 
monophasic increase of BNP/NT-proBNP level, which peaks 
during the first 24 hours of MI. It was shown that in patients 
with high initial NT-proBNP level absence of its fast decrease 
after myocardial injury was associated with unfavourable short-
term prognosis. Prolonged increase of this peptide level is asso-
ciated with refractory ischemia and high risk of ischemic events 
in patients with MI without ST segment elevation [11]. 
Our data suggest that NT proBNP level increase can be 
utilized as AF predictor in STEMI patients and as predictor of 
adverse events in patients with STEMI and AF.
NT proBNP 
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Fig. 2. ROC-curve for prediction of MACEs in STEMI patients using NT proBNP level
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